{"Answer": "Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer\n\nAdjuvant therapy with an aromatase inhibitor improves outcomes , as compared with tamoxifen , in postmenopausal women with hormone-receptor -- positive breast cancer .\n\nIn two phase 3 trials , we randomly assigned premenopausal women with hormone-receptor -- positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years . Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin , oophorectomy , or ovarian irradiation . The primary analysis combined data from 4690 patients in the two trials .\n\nAfter a median follow-up of 68 months , disease-free survival at 5 years was 91.1 % in the exemestane -- ovarian suppression group and 87.3 % in the tamoxifen -- ovarian suppression group ( hazard ratio for disease recurrence , second invasive cancer , or death , 0.72 ; 95 % confidence interval ( CI ) , 0.60 to 0.85 ; P ( 0.001 ) . The rate of freedom from breast cancer at 5 years was 92.8 % in the exemestane -- ovarian suppression group , as compared with 88.8 % in the tamoxifen -- ovarian suppression group ( hazard ratio for recurrence , 0.66 ; 95 % CI , 0.55 to 0.80 ; P ( 0.001 ) . With 194 deaths ( 4.1 % of the patients ) , overall survival did not differ significantly between the two groups ( hazard ratio for death in the exemestane -- ovarian suppression group , 1.14 ; 95 % CI , 0.86 to 1.51 ; P = 0.37 ) . Selected adverse events of grade 3 or 4 were reported for 30.6 % of the patients in the exemestane -- ovarian suppression group and 29.4 % of those in the tamoxifen -- ovarian suppression group , with profiles similar to those for postmenopausal women .\n\nIn premenopausal women with hormone-receptor -- positive early breast cancer , adjuvant treatment with exemestane plus ovarian suppression , as compared with tamoxifen plus ovarian suppression , significantly reduced recurrence . ( Funded by Pfizer and others ; TEXT and SOFT ClinicalTrials . gov numbers ,  NCT00066703  and  NCT00066690  , respectively . )\n\n", "Topic": "breast", "Question": "NEJMoa1404037", "level": 0, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "88.8 %": ["Outcomes"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"], "adverse event": ["Outcomes"], "30.6 %": ["Outcomes"], "29.4 %": ["Outcomes"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "88.8 %": ["Effect-strength"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"], "adverse event": ["Adverse-effects"], "30.6 %": ["Adverse-effects"], "29.4 %": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "A", "A"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Age": [], "Condition": ["A"], "Location": [], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Intensity": [], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["A"], "Adverse-effects": ["A"], "Conclusion-general": ["A"]}, "Count": 1}, "Doggos_text": {"Sex": "The participants were women.", "Condition": "The participants were premenopausal and had hormone-receptor positive early breast cancer.", "Sample-size": "There were 4690 patients.", "Intervention-general": "The study assessed the impact of exemestane with ovarian suppression.", "Duration": "Participants received the intervention for a period of 5 years.", "Control": "A comparison group was assigned tamoxifen plus ovarian suppression.", "Outcomes-general": "The study assessed the recurrence of breast cancer and the survival of patients.", "Effect-strength": "The rate of freedom from breast cancer at 5 years was 92.8% in the examestane group, and 88.8% in the tamoxifen group. The disease-free survival at 5 years was 91.1% in the examestane group and 87.3% in the tamoxifen group. Overall survival did not differ significantly between the two groups.", "Adverse-effects": "Selected adverse events of grade 3 or 4 were reported for 30.6% of the patients in the examestane group and 29.4% of the tamoxifen group.", "Conclusion-general": "In pre-menopausal women with hormone-receptor early breast cancer, treatment with examestane plus ovarian suppression significantly reduced the recurrence of cancer when compared with treatment with tamoxifen with ovarian suppression."}, "id": "NEJMoa1404037", "children": [{"Answer": "Pre-menopausal women with hormone-receptor positive (HRP) breast cancer have another promising treatment available to them to reduce recurrence of the disease.  Adjuvant Exemestane with an aromatase inhibitor, or hormone receptor, is shown to improve outcomes, as compared to tamoxifen plus ovarian suppression. A five-year follow-up in the  Exemestane group showed a disease-free survival rate at 91.1 % compared to the Tamoxifen group with a 87.3% survival rate. The rate of freedom from cancer at five years was at nearly 93% in the Exemestane group as compared to about 89% in the Tamoxifen group. In the study of 4690 patients, there were 194 deaths. The overall survival rate did not differ significantly between the two groups. Adverse reactions were similar in both groups. This is great news for women looking for an alternative treatment to suppress the chance of HRP breast cancer returning.\r", "AssignmentId": "3WMINLGALCOLOX0EFDGC7W577LYCAK", "Question": "NEJMoa1404037", "WorkerId": "A2KROBPV0YPE4A", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "40-60", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "A", "b"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["A"], "Adverse-effects": ["b"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK", "children": [{"Answer": "For pre-menopausal women with hormone-receptor positive (HRP) breast cancer, there is another promising treatment available. This treatment is called Adjuvant Exemestane with an aromatase inhibitor. It is also called hormone receptor. A five-year follow up study has shown that, compared to the Tamoxifen treatment, Exemsestane had a higher disease-free survival rate and a higher rate of freedom from cancer. This is great news for women looking for an alternative treatment to suppress the likelihood of HRP breast cancer returning. ", "AssignmentId": "32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS", "Question": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK", "WorkerId": "AJXWXKU4SX70U", "Qualification": 0.6153846153846154, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "female", "Age": "24-39", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["B", "A", "B"], "Outcomes": ["A", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS", "children": [{"Answer": "Adjuvant Exemestane with an aromatase inhibitor has a higher disease-free survival rate and freedom from cancer rate than Tamoxifen in pre-menopausal women with hormone-receptor positive breast cancer. This was shown in a 5 year follow up study.", "AssignmentId": "3QIYRE09Y428LDK58KWXC66G4SQN15", "Question": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS", "WorkerId": "A122XBTHLAFX51", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "female", "Age": "40-60", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["C", "B", "A"], "Outcomes": ["A", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15", "children": [{"Answer": "Pre-menopausal women with hormone-receptor positive breast cancer using exemestane had a higher survival rate than those on tamoxifen. ", "AssignmentId": "374TNBHA8CGQEG8001VNUNCVKEFQY6", "Question": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15", "WorkerId": "A3D8ZG1VV5FO35", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "female", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "C"], "Intervention": ["B", "C", "B"], "Outcomes": ["A", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15_374TNBHA8CGQEG8001VNUNCVKEFQY6", "children": [{"Answer": "Breast cancer patients show higher survival on exemestane then tamoxifen. ", "AssignmentId": "352YTHGROWYX3GVDS4KM5KGNYXYH48", "Question": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15_374TNBHA8CGQEG8001VNUNCVKEFQY6", "WorkerId": "ADGH08WUP68ZF", "Qualification": 0.9230769230769231, "Topic": "breast", "Hop": 4, "Education": "Some College", "Gender": "female", "Age": "15-24", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["B", "C", "C"], "Intervention": ["B", "C", "B"], "Outcomes": ["A", "D", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["D"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3WMINLGALCOLOX0EFDGC7W577LYCAK_32UTUBMZ7HHM6GB6C8BDSZD2BWLVBS_3QIYRE09Y428LDK58KWXC66G4SQN15_374TNBHA8CGQEG8001VNUNCVKEFQY6_352YTHGROWYX3GVDS4KM5KGNYXYH48"}]}]}]}]}, {"Answer": "In premenopausal breast cancer (specifically the early, hormone receptor positive kind), treatment with a therapy called aromatase inhibitor is better than another drug called tamoxifen. They found this by studying the clinical trial data from 4690 patients from two separate trials. The 5 year survival rate was 91% for aromatase inhibitor and 87% for tamoxifen. The researchers had a fairly high confidence in that result. However, the group that was treated with the aromatase inhibitor had a slightly elevated risk for adverse side effects as opposed to those treated with the tamoxifen. In summary, the research found that women treated with adjuvant treatment with exemstane plus ovarian suppression medication were more likely to stay in remission after their breast cancer had been treated, as opposed to the tamoxifen group. This study was paid for by Pfizer and is publicly available online.", "AssignmentId": "3VHP9MDGRO5GKOHMQT24LXGY48MFCP", "Question": "NEJMoa1404037", "WorkerId": "A2WNTEVRT68JXT", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "24-39", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "B"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["B"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP", "children": [{"Answer": "Treatment with an aromatase inhibitor is better than treatment with tamoxifen in premenopausal breast cancer, especially early, hormone receptor positive kind. Two separate trials, by Pfizer, of 4690 women showed that the 5 year survival rate was 91% with aromatase inhibitor and 87% for tamoxifen. They also had only slightly more adverse side effects than those given tamoxifen. The research found that women treated with adjuvant treatment with exemstane plus ovarian suppression medication were also more likely to stay in remission.", "AssignmentId": "31T4R4OBOT135V2G8A4SX53H7ZR7CW", "Question": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP", "WorkerId": "A122XBTHLAFX51", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "female", "Age": "40-60", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "B"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["B"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW", "children": [{"Answer": "Two separate trials by Pfizer showed the 5 year survival rate was 91% with aromatase inhibitor and 87% for tamoxifen. There was slightly more adverse side effects then with tamoxifen. Research found adjuvant w/ovarian suppression were more likely to stay in remission. ", "AssignmentId": "3ITXP059PX4CW7SE65JPF0C8L8ASJ2", "Question": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW", "WorkerId": "A2YUCJ28XANFOX", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 2, "Education": "High School", "Gender": "female", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["B", "A", "B"], "Outcomes": ["A", "C", "B"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["B"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2", "children": [{"Answer": "Trials by Pfizer showed 5 year survival rate was 91% with aromatase inhibitor and 87% for tamoxifen. Side effects rates differ.", "AssignmentId": "32EYX73OY1U9983V3FNYWSGNKDFURO", "Question": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2", "WorkerId": "A1S1K7134S2VUC", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "male", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"5 year": ["Duration"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["A", "B", "C"], "Outcomes": ["B", "B", "B"], "Conclusion": ["C"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["B"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2_32EYX73OY1U9983V3FNYWSGNKDFURO", "children": [{"Answer": "Trials show a higher survival rate with aromatase inhibitor than tamoxifen.", "AssignmentId": "3ZPBJO59KQMA3CE6LFLF8OATBB4HD0", "Question": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2_32EYX73OY1U9983V3FNYWSGNKDFURO", "WorkerId": "AAB13RUHSABEV", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "female", "Age": "40-60", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3VHP9MDGRO5GKOHMQT24LXGY48MFCP_31T4R4OBOT135V2G8A4SX53H7ZR7CW_3ITXP059PX4CW7SE65JPF0C8L8ASJ2_32EYX73OY1U9983V3FNYWSGNKDFURO_3ZPBJO59KQMA3CE6LFLF8OATBB4HD0"}]}]}]}]}, {"Answer": "This study found that in postmenopausal women with hormone receptor-positive breast cancer and when compared to tamofoxifen, that adjuvant therapy with an aromatase inhibitor improves outcomes. During two phase 3 trials the primary analysis used data from 4690 patients. Ovarian estrogen production was achieved with the use of the gonadotropin releasing hormone agoinsts triptorellin, oophoroectomy, or ovarian irraditation. Findings concluded that in premenopausal women  with hormone receptor -positive breast cancer that tamoxifen plus ovarian suppression and adjuvant treatment with exemestane plus ovarian suppression ended up significantly reducing recurrence. A median follow up of 68 months disease free survival was 91.1%.The rate of freedom from breast cancer at five years was 92.8% for this group of women involved. A well executed study for the cancer researchers involved. Postmenopausal women achieved the same outcomes thus proving pre or post menopause did not matter.", "AssignmentId": "3SBEHTYCWOODXIKHNTQELLL9OTOYIA", "Question": "NEJMoa1404037", "WorkerId": "A1AZV2XOQK7RSW", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "40-60", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA", "children": [{"Answer": "For postmenopausal women with breast cancer the adjuvant therapy worked better than tamofoxifen. The researchers used analysis from 4690 patients who were in the trials. In pre-menopausal women with this specific type of breast cancer had a significant reduction in recurrence when taking tamoflexin with ovarian suppression and the treatment that is the topic of this trial. After a follow up 68 moths later the survival rate was about 91% and the survival rate at five years cancer free was about 92%. Postmenopausal women had similar outcomes. ", "AssignmentId": "39L1G8WVWRC1H9RVQ1CI3S8AY3K319", "Question": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA", "WorkerId": "A2X0O6DN8NQWCJ", "Qualification": 0.5384615384615384, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "female", "Age": "24-39", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["D", "A", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["D"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319", "children": [{"Answer": "Analysis from 4690 patients in this trial with premenopasual symptoms had a reduction in recurrence when taking tamoflexin w/ovarian suppression. After a 68 months the survival rate was 91% of and  at 5 years cancer free was 92%. Postmenopusal women had similar outcomes. ", "AssignmentId": "3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6", "Question": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319", "WorkerId": "A2YUCJ28XANFOX", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 2, "Education": "High School", "Gender": "female", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "woman": ["Participants"], "survival": ["Outcomes"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "woman": ["Sex"], "survival": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "A"], "Intervention": ["C", "A", "A"], "Outcomes": ["B", "B", "C"], "Conclusion": ["C"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["A"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6", "children": [{"Answer": "Women taking tamoflexin w/ovarian suppression had a survival rate of 91% after 68 months and after five years, 92% were cancer free.", "AssignmentId": "3ZSY5X72NYWEW3JY7TBPXMOY2RTOR7", "Question": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6", "WorkerId": "A2IXFVW8GE5NYE", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 3, "Education": "Some College", "Gender": "male", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "woman": ["Participants"], "survival": ["Outcomes"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "woman": ["Sex"], "survival": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "C"], "Intervention": ["A", "C", "B"], "Outcomes": ["B", "B", "C"], "Conclusion": ["C"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6_3ZSY5X72NYWEW3JY7TBPXMOY2RTOR7", "children": [{"Answer": "now a days women suffered from cancer and after 5 years 92% reduced.", "AssignmentId": "3QAVNHZ3ENPER1UKSQ9BAFVU7TWLAX", "Question": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6_3ZSY5X72NYWEW3JY7TBPXMOY2RTOR7", "WorkerId": "A1RVRSK2GTUVGK", "Qualification": 0.5384615384615384, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "female", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "woman": ["Participants"]}, "Fine": {"5 year": ["Duration"], "woman": ["Sex"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "C"], "Intervention": ["C", "A", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["C"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["C"], "Outcomes-general": ["C"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_3SBEHTYCWOODXIKHNTQELLL9OTOYIA_39L1G8WVWRC1H9RVQ1CI3S8AY3K319_3X1FV8S5JYCIXXJHSU3RTA4ZSKNVG6_3ZSY5X72NYWEW3JY7TBPXMOY2RTOR7_3QAVNHZ3ENPER1UKSQ9BAFVU7TWLAX"}]}]}]}]}, {"Answer": "In 2 phase 3 trials, randomly assigned premenopausal women w/ hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or taxoifen plus ovarian suppression for a 5-year period. Suppression of ovarian estrogen production was achieved with using gonadotropin-releasing-hormone agonist triptorelin, oophorectomy or ovarian irradiation. The primary analysis combined data from 4690 patients in 2 trials. After a median f/u of 68 months, disease-free  survival at 5 years was 91.1% in exemestane group & 87.3% in tamoxifen group. The rate of no breast cancer at 5 years was 92.8% in the exemestane group & 88.8% in the tamoxifen group. With 194 deaths, overall survival did not differ much between the 2 groups. Selected adverse events of grade 3 or 4 were reported for 30.6% of patients in the exemestane grp & 29.4% in the tamoxifen group, similar to those for postmenopausal women. In premenopausal women with hormone-receptor, positive early breast cancer adjuvant treatment w/ exemestane plus ovarian suprression significantly reduced recurrence. ", "AssignmentId": "352YTHGROWYX3GVDS4KM5KGNTIO4HM", "Question": "NEJMoa1404037", "WorkerId": "A98E8M4QLI9RS", "Qualification": 1.0, "Topic": "breast", "Hop": 0, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "88.8 %": ["Outcomes"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"], "adverse event": ["Outcomes"], "30.6 %": ["Outcomes"], "29.4 %": ["Outcomes"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "88.8 %": ["Effect-strength"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"], "adverse event": ["Adverse-effects"], "30.6 %": ["Adverse-effects"], "29.4 %": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "A", "A"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["A"], "Adverse-effects": ["A"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM", "children": [{"Answer": "In these trials,2 groups of women were studied. The first group was given exemestane w/ovarian suppression. The other group was given taxifen w/ovarian suppression for 5 years. At the end of the trial the survival rate was 91.1% for the exemenstane group and 87.3% in the tamoxifen group.  There was 194 deaths overall. 30.6% of patients in the exemestane group reported adverse side effects and 29.4% in the tamoxifen group. Exemestane plus ovarian suppression significantly reduced reoccurrence. ", "AssignmentId": "39GXDJN2OUZ34IDZ9WR31XN13VUV8X", "Question": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM", "WorkerId": "A2YUCJ28XANFOX", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 1, "Education": "High School", "Gender": "female", "Age": "24-39", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "woman": ["Participants"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"], "30.6 %": ["Outcomes"], "29.4 %": ["Outcomes"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "woman": ["Sex"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"], "30.6 %": ["Adverse-effects"], "29.4 %": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "C"], "Intervention": ["A", "A", "A"], "Outcomes": ["B", "B", "A"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["A"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X", "children": [{"Answer": "Exemestane plus ovarian surpression significantly reduces reoccurrence of cancer. The result of a 5 year study with two groups: one given extemestane and the other tamoxifen, both had ovarian suppression. Survival rate for exemenstane was 91.1% versus 87.3% for tamoxifen.", "AssignmentId": "3TE22NPXPCX3R47IDX03BV7JPVK44J", "Question": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X", "WorkerId": "AVBRJBJONL47I", "Qualification": 0.9230769230769231, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "female", "Age": "40-60", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["A", "A", "A"], "Outcomes": ["B", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J", "children": [{"Answer": "Exemestane plus ovarian surpression reduces reoccurrence of cancer and had a higher survival rate versus tamoxifen.", "AssignmentId": "3P529IW9KZ69NSBS36V3OG6L4XFFLM", "Question": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J", "WorkerId": "A2WETCIWJT79CQ", "Qualification": 0.6923076923076923, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "female", "Age": "24-39", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["A", "C", "A"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J_3P529IW9KZ69NSBS36V3OG6L4XFFLM", "children": [{"Answer": "Tamoxifen had lower survival rate then Extemestane w/ovarian suppression.", "AssignmentId": "3MAOD8E57RVGBE5YFDH47FAHD4CNX2", "Question": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J_3P529IW9KZ69NSBS36V3OG6L4XFFLM", "WorkerId": "ADGH08WUP68ZF", "Qualification": 0.9230769230769231, "Topic": "breast", "Hop": 4, "Education": "Some College", "Gender": "female", "Age": "15-24", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["A", "C", "A"], "Outcomes": ["B", "D", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["A"], "Duration": ["C"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["D"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_352YTHGROWYX3GVDS4KM5KGNTIO4HM_39GXDJN2OUZ34IDZ9WR31XN13VUV8X_3TE22NPXPCX3R47IDX03BV7JPVK44J_3P529IW9KZ69NSBS36V3OG6L4XFFLM_3MAOD8E57RVGBE5YFDH47FAHD4CNX2"}]}]}]}]}, {"Answer": "Testing over several years has proven that an aromatase inhibitor (exemestane) improves outcomes for post-menopausal women with hormone-receptor positive breast cancer. The women all went through ovarian suppression via different methods, but survival rate after five and a half years was higher for those who went through ovarian suppression while taking exemestane than those who went through it taking tamoxifen. In addition, more women were free from breast cancer after five years that had been taking the exemestane as opposed to those who took tamoxifen. The treatment was also found to be helpful for pre-menopausal women with hormone-receptor positive early breast cancer. \r4690 patients were tested during these trials over more than five years, and the results indicate that the aromatase inhibitor exemestane was overall the more successful drug treatment when compared to tamoxifen and combined with suppression of ovarian estrogen production. ", "AssignmentId": "3XIQGXAUMDTR8TDBZ60FBIOR8B77XE", "Question": "NEJMoa1404037", "WorkerId": "AUPHYAKC58LPA", "Qualification": 0.46153846153846156, "Topic": "breast", "Hop": 0, "Education": "Some College", "Gender": "female", "Age": "24-39", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "C", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE", "children": [{"Answer": "Testing has shown that an aromatase inhibitor (exemestane) improves the outcome in post-menopausal women with breast cancer. 4690 patients were tested over the 5 year time frame. All women in the test did go through ovarian suppression via different methods. The survival rate, after 5 1/2 years, was higher for those also taking exemestane as opposed to tamoxifen. The rate of women who were free of cancer after 5 years was also higher for those taking exemestane. The treatment was found to also aid pre-menopausal women.", "AssignmentId": "3OHYZ19UGDQMXMXH5IP32WZOXTGOAH", "Question": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE", "WorkerId": "A2WP9EC483LJY4", "Qualification": 0.5384615384615384, "Topic": "breast", "Hop": 1, "Education": "Some College", "Gender": "male", "Age": "24-39", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "D", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["D"]}, "Fine": {"Sex": ["A"], "Condition": ["D"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["D"]}}, "id": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH", "children": [{"Answer": "A study testing 4690 women over 5 years showed that an aromatase inhibtor improves the outcome of post-menopausal women with breast cancer. The survival rate and those cancer-free after 5 years were higher for those taking exemestane for both pre- and post-menopausal women.", "AssignmentId": "3LBXNTKX0SGVMC14E3YZPEFX4IS9XO", "Question": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH", "WorkerId": "A9BVDYQU2VTIJ", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "male", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "D", "A"], "Intervention": ["B", "A", "C"], "Outcomes": ["B", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["D"], "Sample-size": ["A"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO", "children": [{"Answer": "A study of 4690 women shows the survival and cancer-free rate after 5 years was higher when taking exemestane  pre & post menopausal women", "AssignmentId": "33LK57MYLUQ2WMXIORMB3U0Y8WMZSD", "Question": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO", "WorkerId": "A98E8M4QLI9RS", "Qualification": 1.0, "Topic": "breast", "Hop": 3, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "5 year": ["Intervention"], "woman": ["Participants"], "survival": ["Outcomes"], "exemestane": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "5 year": ["Duration"], "woman": ["Sex"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "D", "A"], "Intervention": ["B", "A", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["D"], "Sample-size": ["A"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO_33LK57MYLUQ2WMXIORMB3U0Y8WMZSD", "children": [{"Answer": "Women who took exemestane showed higher survival rate.", "AssignmentId": "33M4IA01QHM1QCXQ8KYLGZFRE3HRXE", "Question": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO_33LK57MYLUQ2WMXIORMB3U0Y8WMZSD", "WorkerId": "A1AZV2XOQK7RSW", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "female", "Age": "40-60", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"woman": ["Participants"], "survival": ["Outcomes"], "exemestane": ["Intervention"]}, "Fine": {"woman": ["Sex"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["B", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3XIQGXAUMDTR8TDBZ60FBIOR8B77XE_3OHYZ19UGDQMXMXH5IP32WZOXTGOAH_3LBXNTKX0SGVMC14E3YZPEFX4IS9XO_33LK57MYLUQ2WMXIORMB3U0Y8WMZSD_33M4IA01QHM1QCXQ8KYLGZFRE3HRXE"}]}]}]}]}, {"Answer": "Adjuvant therapy with an aromatase inhibitor improves outcomes when compared to tamokifen, in postmenopausal women with hormone-receptor positive breast cancer. Trials were done in which women with hormone receptor positive early breast cancer were assigned to one of two groups, those with the aromatase inhibitor or those with tamokifen. These trials lasted for a period of five years. A total of 4,690 patients were studied in two trials that contained three phases per trial. At the 68 month follow up, disease free survival was found to be higher in the aromatase inhibitor group over the tamokifen group with a confidence interval of 95%. The rate of freedom from breast cancer was higher in the aromatase inhibitor group than the tamokifen group. With a death rate of 4.1%, overall survival did not differ significantly between the two groups. Adverse events were reported at a higher rate in the group with the aromatase inhibitor than the group with tamokifen.", "AssignmentId": "3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ", "Question": "NEJMoa1404037", "WorkerId": "AWCD7E12GSX2Z", "Qualification": 0.6153846153846154, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "24-39", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"early breast cancer": ["Participants"], "5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "adverse event": ["Outcomes"]}, "Fine": {"early breast cancer": ["Condition"], "5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "adverse event": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "D", "A"], "Intervention": ["C", "A", "B"], "Outcomes": ["A", "B", "B"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["D"], "Sample-size": ["A"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["B"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ", "children": [{"Answer": "A trial that lasted five years has shown that Adjuvant therapy with an aromatase inhibitor improves outcome when compared to Tamokifen. These trials lasted 5 years and studied a total of approximately 4,700 patients. After a follow up at the 68 month mark the survival rate was found to be higher in the aromatase inhibitor group over the Tamokifen group and with a 95% confidence rate. Also the adverse events reported at a higher rate in the aromatase inhibitor group.", "AssignmentId": "37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H", "Question": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ", "WorkerId": "A1AZV2XOQK7RSW", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "female", "Age": "40-60", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "survival": ["Outcomes"], "adverse event": ["Outcomes"]}, "Fine": {"5 year": ["Duration"], "survival": ["Outcomes-general"], "adverse event": ["Adverse-effects"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "A"], "Intervention": ["C", "A", "B"], "Outcomes": ["B", "B", "D"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["A"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["D"], "Adverse-effects": ["B"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H", "children": [{"Answer": "There was a trial that lasted five years that showed Adjuvant therapy as well as aromatase inhibitor improves the outcome, when you compare it to Tamokifen. They studied roughly 4,700 patients. Survival rate was found to be higher in the inhibitor group than the Tamokifen.", "AssignmentId": "32ZKVD547G82U79NSY5794LJLNS3BQ", "Question": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H", "WorkerId": "A1E88GHZQWP0QT", "Qualification": 0.6923076923076923, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "female", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "survival": ["Outcomes"]}, "Fine": {"5 year": ["Duration"], "survival": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "A"], "Intervention": ["C", "A", "B"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["A"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ", "children": [{"Answer": "A five-year study showed higher cancer survival rates using Adjuvant therapy with an aromatase inhibitor compared to just Tomokifen.", "AssignmentId": "3V0Z7YWSIZLSI3BATFI2R6AYMSBV22", "Question": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ", "WorkerId": "A2KROBPV0YPE4A", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "female", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "survival": ["Outcomes"]}, "Fine": {"5 year": ["Duration"], "survival": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["B", "A", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ_3V0Z7YWSIZLSI3BATFI2R6AYMSBV22", "children": [{"Answer": "Survival is better with Adjuvant than just Tomokifen.", "AssignmentId": "37W3JXSD67TVYD4MCAUTMCUH8JXWYP", "Question": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ_3V0Z7YWSIZLSI3BATFI2R6AYMSBV22", "WorkerId": "A2B115J2WDWGNM", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "female", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"survival": ["Outcomes"]}, "Fine": {"survival": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["C"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["C"]}}, "id": "NEJMoa1404037_3N4BPTXIO9DNM4Q0DVE1VGU9KHTUKQ_37WLF8U1WQB2KT0ZHDGYFAGTHXAK6H_32ZKVD547G82U79NSY5794LJLNS3BQ_3V0Z7YWSIZLSI3BATFI2R6AYMSBV22_37W3JXSD67TVYD4MCAUTMCUH8JXWYP"}]}]}]}]}, {"Answer": "Studies have shown improved patient outcomes in postmenopausal women with hormone-receptor positive breast cancer who received adjuvant therapy with an aromatase inhibitor as compared to tamoxifen. In two phase 3 randomized controlled trials of nearly 4700 premenopausal women with hormone-receptor positive breast cancer, adjuvant therapy with exemestane in combination with ovarian suppression showed significantly higher rates of disease-free survival at 5 years and freedom from breast cancer at 5 years as compared to tamoxifen in combination with ovarian suppression. The rates of overall survival as well as grade 3 or 4 adverse effects were not significantly different among the two groups. The results of these two trials in premenopausal women support those of previously published studies examining the effects of adjuvant aromatase inhibitors compared to tamoxifen in postmenopausal women with hormone-receptor positive breast cancer.", "AssignmentId": "31LM9EDVOMDFGU09Y923G622XW5NJX", "Question": "NEJMoa1404037", "WorkerId": "A3K7OKFT05A073", "Qualification": 1.0, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "male", "Age": "24-39", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "C", "B"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["B"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX", "children": [{"Answer": "Studies have shown that patient outcomes are better in postmenopausal women that receive adjuvant therapy with an aromatase inhibitor instead of tamoxifen. Controlled trials demonstrated that adjuvant therapy showed a higher rate of survival at 5 years. However the overall survival and grade 3 or 4 adverse effects were not significantly different between the two groups. The results support previous published studies examining the effects of the two treatments. ", "AssignmentId": "3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6", "Question": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX", "WorkerId": "A5PUKKK7BIV3", "Qualification": 0.9230769230769231, "Topic": "breast", "Hop": 1, "Education": "Some College", "Gender": "female", "Age": "40-60", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "woman": ["Participants"], "survival": ["Outcomes"], "tamoxifen": ["Intervention"]}, "Fine": {"5 year": ["Duration"], "woman": ["Sex"], "survival": ["Outcomes-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "C"], "Intervention": ["B", "A", "C"], "Outcomes": ["C", "B", "B"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["B"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6", "children": [{"Answer": "In women who take adjuvant therapy with an aromatase inhibitor for breast cancer, five year survival rates are higher than if that women had just taken tamosifen. However, long term survival rates were the same for both groups.", "AssignmentId": "34HJIJKLP6H2LHQXXT1QKL7W2F0V45", "Question": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6", "WorkerId": "A2WNTEVRT68JXT", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "female", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"]}, "Fine": {"5 year": ["Duration"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "C"], "Intervention": ["A", "B", "B"], "Outcomes": ["B", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45", "children": [{"Answer": "Women have better breast cancer success rates taking adjuvant therapy with an aromatase inhibitor than taking tamosifen.", "AssignmentId": "3JJVG1YBECI58MWR6HT0O1J3398B5X", "Question": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45", "WorkerId": "A2JTV44ZIGMS5D", "Qualification": 0.6153846153846154, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "male", "Age": "40-60", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"woman": ["Participants"], "breast cancer": ["Outcomes"]}, "Fine": {"woman": ["Sex"], "breast cancer": ["Outcomes-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "C", "C"], "Intervention": ["C", "C", "B"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["C"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45_3JJVG1YBECI58MWR6HT0O1J3398B5X", "children": [{"Answer": "Adjuvant therapy with an aromatose inhibitor is better than tamosifen", "AssignmentId": "3Q5C1WP23NM4VOEZ4K0BIP6UH1H51G", "Question": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45_3JJVG1YBECI58MWR6HT0O1J3398B5X", "WorkerId": "A1KR3HNLXSLC10", "Qualification": 0.6923076923076923, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "male", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {}, "Fine": {}}, "Doggos_crowd": {"Coarse": {"Participants": ["C", "C", "C"], "Intervention": ["B", "C", "B"], "Outcomes": ["C", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["C"], "Condition": ["C"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["B"], "Outcomes-general": ["C"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_31LM9EDVOMDFGU09Y923G622XW5NJX_3LKC68YZ3BOJ4Z0K6NLVKLWFP53WO6_34HJIJKLP6H2LHQXXT1QKL7W2F0V45_3JJVG1YBECI58MWR6HT0O1J3398B5X_3Q5C1WP23NM4VOEZ4K0BIP6UH1H51G"}]}]}]}]}, {"Answer": "We have an extraordinary study of the benefits of using Adjuvant Exemestane with ovarian suppression in premenopausal breast cancer compared to patients using Tamoxifen with ovarian suppression. In the study, primary analysis combined data from 4690 patients in two trials.  In 2 phase 3 trials,  randomly assigned premenopausal women (a woman usually in her 40s have menstrual irregularity experience menopause symptoms)  with hormone-receptor early breast cancer to the aromatase inhibitor exemestan plus ovarian suppression or tamoxifen plus ovarian suppression, suppression of the ovarian estrogen was achieved with the used of gonadotropin-releasing hormone agonist triptorelin, oophorectomy or ovarian irradiation.\r\rIn the follow up of 5 years, we had disease-free survival of exemestane 91.1% compared to tamoxifen 87.3%. The freedom of breast cancer at 5yrs, exemestane was 92.8% compared to tamoxifen 88.8%. With deaths of 4.1%, there wasn't much difference between the two groups.  In conclusion, patients using exemestane had significantly reduced recurrence compared to tamoxifen.", "AssignmentId": "3JCG6DTRV4BH5EHE9RETH19TG3SQQO", "Question": "NEJMoa1404037", "WorkerId": "A3MV3MK1DR9MNZ", "Qualification": 0.5384615384615384, "Topic": "breast", "Hop": 0, "Education": "College", "Gender": "female", "Age": "40-60", "level": 1, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "early breast cancer": ["Participants"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "88.8 %": ["Outcomes"], "91.1 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "survival": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "early breast cancer": ["Condition"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "88.8 %": ["Effect-strength"], "91.1 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "survival": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "A", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["B", "A", "C"], "Conclusion": ["A"]}, "Fine": {"Sex": ["A"], "Condition": ["A"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["B"], "Effect-strength": ["A"], "Adverse-effects": ["C"], "Conclusion-general": ["A"]}}, "id": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO", "children": [{"Answer": "They performed a study comparing the treatments of exemestane in premenopausal breast cancer compared to patients using tamoxifen (both with ovarian suppression). The study combined data from 4690 patients in two phase 3 trials, randomly assigning the women into either the exemestane or the tamoxifen group. The study found at follow-up 5 years later that a higher percentage of women in the exemestane group (92.8%) were free of breast cancer compared to the tamoxifen group (87.3%). There was no difference in deaths between groups however.", "AssignmentId": "3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL", "Question": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO", "WorkerId": "A3LW4YHAM1JH1X", "Qualification": 0.8461538461538461, "Topic": "breast", "Hop": 1, "Education": "College", "Gender": "male", "Age": "24-39", "level": 2, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"4690": ["Participants"], "ovarian suppression": ["Intervention"], "5 year": ["Intervention"], "92.8 %": ["Outcomes"], "87.3 %": ["Outcomes"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"4690": ["Sample-size"], "ovarian suppression": ["Intervention-general"], "5 year": ["Duration"], "92.8 %": ["Effect-strength"], "87.3 %": ["Effect-strength"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "A"], "Intervention": ["A", "A", "A"], "Outcomes": ["A", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["A"], "Intervention-general": ["A"], "Duration": ["A"], "Control": ["A"], "Outcomes-general": ["A"], "Effect-strength": ["B"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL", "children": [{"Answer": "A study compared the treatments of exemestane and tamoxifen in premenopausal breast cancer. The study found 5 years later that a higher percentage of women taking exemestane were free of breast cancer compared to those taking tamoxifen. There was no difference in deaths.", "AssignmentId": "3RKNTXVS3NJITTNZMYAUOYTJH564AK", "Question": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL", "WorkerId": "A2ELH7YDLFNJUZ", "Qualification": 1.0, "Topic": "breast", "Hop": 2, "Education": "College", "Gender": "male", "Age": "24-39", "level": 3, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"5 year": ["Intervention"], "premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"], "tamoxifen": ["Intervention"]}, "Fine": {"5 year": ["Duration"], "premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"], "tamoxifen": ["Control"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "C"], "Intervention": ["B", "A", "B"], "Outcomes": ["A", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["A"], "Control": ["B"], "Outcomes-general": ["A"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK", "children": [{"Answer": "A recent study found that when treating premenopausal breast cancer a higher percent of women taking exemestane were free of cancer.", "AssignmentId": "3I33IC7ZWGN8QF8CIKR6VJWL1I82A6", "Question": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK", "WorkerId": "AD70PPBAJSCPV", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 3, "Education": "College", "Gender": "male", "Age": "24-39", "level": 4, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"]}, "Fine": {"premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["C", "B", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK_3I33IC7ZWGN8QF8CIKR6VJWL1I82A6", "children": [{"Answer": "Exemestane led to more premenopausal women being free of breast cancer.", "AssignmentId": "3KOPY89HM9N8CQ7ZGQIO7S4WXO2J3O", "Question": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK_3I33IC7ZWGN8QF8CIKR6VJWL1I82A6", "WorkerId": "A3BDVHNMJECSKG", "Qualification": 0.7692307692307693, "Topic": "breast", "Hop": 4, "Education": "College", "Gender": "female", "Age": "24-39", "level": 5, "branch": "NEJMoa1404037", "Tagging": {"Coarse": {"premenopausal": ["Participants"], "woman": ["Participants"], "breast cancer": ["Outcomes"], "exemestane": ["Intervention"]}, "Fine": {"premenopausal": ["Condition"], "woman": ["Sex"], "breast cancer": ["Outcomes-general"], "exemestane": ["Intervention-general"]}}, "Doggos_crowd": {"Coarse": {"Participants": ["A", "B", "C"], "Intervention": ["B", "C", "C"], "Outcomes": ["B", "C", "C"], "Conclusion": ["B"]}, "Fine": {"Sex": ["A"], "Condition": ["B"], "Sample-size": ["C"], "Intervention-general": ["B"], "Duration": ["C"], "Control": ["C"], "Outcomes-general": ["B"], "Effect-strength": ["C"], "Adverse-effects": ["C"], "Conclusion-general": ["B"]}}, "id": "NEJMoa1404037_3JCG6DTRV4BH5EHE9RETH19TG3SQQO_3LKC68YZ3BOJ4Z0K6NLVKLWFPC4WOL_3RKNTXVS3NJITTNZMYAUOYTJH564AK_3I33IC7ZWGN8QF8CIKR6VJWL1I82A6_3KOPY89HM9N8CQ7ZGQIO7S4WXO2J3O"}]}]}]}]}]}